Imaging in breast cancer: Magnetic resonance imaging

Lehman, Constance D.; Schnall, Mitchell D.

doi:10.1186/bcr1309

Cited by 76 publications

(42 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although mammography is an effective imaging tool, its limitations include moderate sensitivity and specificity (32); therefore, many other imaging modalities have been investigated to complement and increase the diagnostic accuracy of breast imaging. Ultrasound and MRI are important adjuncts to mammography for both diagnosis and characterization of breast cancer and are routinely used in this role (33,34). Ease of use and real-time imaging capability make breast ultrasound one of the methods of choice for guiding breast biopsies and other interventional procedures (35).…”

Section: Detection and Diagnosis Overviewmentioning

confidence: 99%

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Lee¹,

Rosen²,

Mankoff³

2009

J Nucl Med

View full text Add to dashboard Cite

Breast cancer is the most common non-skin type of cancer and the second leading cause of cancer mortality in women. Advances in diagnosis and treatment have led to declines in mortality, despite an increase in breast cancer incidence. An advancing array of both local and systemic therapy options has led to increasingly individualized treatment. Imaging plays a key role in detecting breast cancer and directing its therapy. This continuing education article, part 1 in a 2-part series, provides a comprehensive review of current and future radiotracer imaging methods applied to breast cancer, in the context of breast cancer management strategies and other nonnuclear imaging methods. Part 1 of the review provides an overview of clinical and biologic considerations in breast cancer and covers radionuclide imaging for detection and staging. Part 2 will cover radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging.

show abstract

Section: Detection and Diagnosis Overviewmentioning

confidence: 99%

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Lee¹,

Rosen²,

Mankoff³

2009

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…62,63 Variations in method of magnetic resonance imaging Magnetic resonance imaging techniques may vary in terms of factors such as the field strength, image sequence parameters and type of coil used. Also, a contrast agent is often administered via intravenous injection during the MR procedure.…”

Section: Magnetic Resonance Imagingmentioning

confidence: 99%

Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation

Cooper

Meng²,

Harnan³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research a...

show abstract

“…Mammography relies on anatomical differences between normal and cancerous tissues, and as such does not provide specific information about the molecular processes and changes at the cellular level. Modalities that offer functional imaging (4), such as positron emission tomography (PET 1 ), single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI), are increasingly gaining importance in breast cancer detection (5)(6)(7)(8). Detection using probes that differentiate between cancerous and normal breast cells at a molecular level provides specific information that can potentially be utilized for earlier detection, therapy response assessment, and overall better management of patients, ultimately leading to a better survival rate.…”

Section: Introductionmentioning

confidence: 99%

Fluorescent Fructose Derivatives for Imaging Breast Cancer Cells

et al. 2007

View full text Add to dashboard Cite

Breast cancer cells are known to overexpress Glut5, a sugar transporter responsible for the transfer of fructose across the cell membrane. Since Glut5 transporter is not significantly expressed in normal breast cells, fructose uptake can potentially be used to differentiate between normal and cancerous cells. Fructose was labeled with two fluorophores at the C-1 position: 7-nitro-1,2,3-benzadiazole (NBD) and Cy5.5. The labeling site was chosen on the basis of the presence and substrate specificity of the key proteins involved in the first steps of fructose metabolism. Using fluorescence microscopy, the uptake of the probes was studied in three breast cancer cell lines: MCF 7, MDA-MB-435, and MDA-MB-231. Both fluorescent fructose derivatives showed a very good uptake in all tested cell lines. The level of uptake was comparable to that of the corresponding glucose analogs, 2-NBDG and Cy5.5-DG. Significant uptake of 1-NBDF derivative was not observed in cells lacking Glut5 transporter, while the uptake of the 1-Cy5.5-DF derivative was independent of the presence of a fructose-specific transporter. While 1-NBDF showed Glut5-specific accumulation, the coupling of a large fluorophore such as Cy5.5 likely introduces big structural and electronic changes, leading to a fructose derivative that does not accurately describe the uptake of fructose in cells.

show abstract

Imaging in breast cancer: Magnetic resonance imaging

Cited by 76 publications

References 25 publications

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation

Fluorescent Fructose Derivatives for Imaging Breast Cancer Cells

Contact Info

Product

Resources

About